$SGMT

Sagimet Biosciences 💛

Sgmt is pioneering a novel approach to drug development through its Fatty Acid Synthase Inhibitors (FASN) a novel class of therapeutics with vast clinical potential. Several diseases are linked to the overproduction of the fatty acid palmitate and sgmt’s clinical pipeline aims to target the dysfunctional metabolic and fibrotic pathways associated with these conditions- chief among them is a metabolic dysfunction associated steatohepatitis a severe liver disorder. 

The FASN pathway is implicated in various other issues ranging from acne to cancer. Sgmt preparing to launch a phase 3 trial for denifanstat and is planning to expand the trial to include patients with f4 mash. The need for treatment is immense with 22 million adults in the u.s. affected and limited options available. Sgmt is also exploring denifanstat as a treatment for aggressive brain cancer. 

Oppenheimer rates Sgmt an outperform along with a 30 dollar price target. With the average price target of 25.33 the upside potential comes in at approx 477 %

477% 👀👀👀

I think it’s like the next ALGS 🤯🤯🤯🤯🤯

Not financial advice!

Much love 💛🍌🍌🍌